Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms

BACKGROUND: Small molecule ONC201 is an investigational anti-tumor agent that upregulates intra-tumoral TRAIL expression and the integrated stress response pathway. A Phase I clinical trial using ONC201 therapy in advanced cancer patients has been completed and the drug has progressed into Phase II...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagner, Jessica, Kline, C. Leah, Zhou, Lanlan, Khazak, Vladimir, El-Deiry, Wafik S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778752/
https://www.ncbi.nlm.nih.gov/pubmed/29357916
http://dx.doi.org/10.1186/s13046-018-0671-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778752/
https://www.ncbi.nlm.nih.gov/pubmed/29357916
http://dx.doi.org/10.1186/s13046-018-0671-0

Ejemplares similares